Transportation Secretary Sean Duffy has confirmed that the US is to phase in ten percent cuts to air travel as safety concerns grow during the ongoing government shutdown. Why Trump’s ‘Mirabella ...

BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another late-stage rare disease win as its eyes an FDA review in 2026. In the ...

Findings showed 76% of patients treated with encaleret achieved both blood and urine calcium levels within the target ranges vs 4% of those on standard of care therapy. Topline data were announced ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Evaxion Biotech ( (EVAX)) just unveiled ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the most promising long-term stocks to buy. On September 6, BridgeBio Pharma announced that its investigational, orally-administered therapy, called ...

DUBLIN, Sept. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav ® (calcium, magnesium, potassium, ...

- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% ...

The Israel Defense Forces' Chief of the General Staff, Lieutenant General Eyal Zamir, revealed Israel's next phase of its war against Hamas on Sunday. Zamir spoke to IDF soldiers during a field tour ...

– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable ...

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...